Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 34 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Papademetriou, Vasilios [Clear All Filters]
Determinants of pulse wave velocity index and potential implementations..
J Clin Hypertens (Greenwich).
(2019). Insomnia and hypertension: A misty landscape..
J Clin Hypertens (Greenwich). 21(6), 835-837.
(2019). Psoriasis and Cardiovascular Disease: Two Sides of the Same Coin?.
Angiology. 69(1), 5-9.
(2018). Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study..
Am J Med. 130(12), 1465.e27-1465.e39.
(2017).
(2017). Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension: a meta-analysis..
J Hypertens. 35(9), 1750-1757.
(2017). Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study..
Am J Nephrol. 45(2), 136-145.
(2017). Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?.
Curr Vasc Pharmacol. 16(1), 30-43.
(2017). Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?.
Curr Vasc Pharmacol. 16(1), 66-69.
(2017). Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?.
Curr Treat Options Cardiovasc Med. 19(5), 39.
(2017). Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients With Hypertension..
J Am Heart Assoc. 6(11),
(2017). Important practice lessons from the SPRINT study beyond the blood pressure goal: all well known and now confirmed..
J Am Soc Hypertens. 10(8), 613-7.
(2016). Renal Sympathetic Denervation: Hibernation or Resurrection?.
Cardiology. 135(2), 87-97.
(2016). Arterial Stiffness and Emerging Biomarkers: Still a Long Journey to Go..
Angiology. 66(10), 901-3.
(2015). Screening for Primary Aldosteronism: Whom and How?.
J Clin Hypertens (Greenwich). 17(7), 547-8.
(2015). Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study..
J Hypertens. 32(2), 415-22.
(2014). Non-interventional management of resistant hypertension..
World J Cardiol. 6(10), 1080-90.
(2014). Renal and cardiac effects of renal sympathetic denervation and carotid baroreceptor stimulation..
Curr Vasc Pharmacol. 12(1), 55-62.
(2014). Renal denervation and Symplicity HTN-3: "Dubium sapientiae initium" (doubt is the beginning of wisdom)..
Circ Res. 115(2), 211-4.
(2014). Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions..
Circulation. 129(13), 1440-51.
(2014). Renal nerve ablation for resistant hypertension: the dust has not yet settled..
J Clin Hypertens (Greenwich). 16(6), 399-400.
(2014). Statin therapy, fitness, and mortality risk in middle-aged hypertensive male veterans..
Am J Hypertens. 27(3), 422-30.
(2014). Gender differences in hypertension: myths and reality..
Curr Hypertens Rep. 15(4), 321-30.
(2013). Carotid baroreceptor stimulation for the treatment of resistant hypertension..
Int J Hypertens. 2011, 964394.
(2011). Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension..
Int J Hypertens. 2011, 196518.
(2011).